Allianz Asset Management
GBT

Allianz Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Allianz Asset Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-401,197
Closed -$27.3M – 2071
2022
Q3 		$27.3M Buy
+401,197
New +$22.1M 0.06% 360
2020
Q4 		– Sell
-14,509
Closed -$800K – 1986
2020
Q3 		$800K Sell
14,509
-6,395
-31% -$406K ﹤0.01% 1492
2020
Q2 		$1.32M Sell
20,904
-8,295
-28% -$569K ﹤0.01% 1755
2020
Q1 		$1.49M Buy
29,199
+2,810
+11% +$188K ﹤0.01% 1630
2019
Q4 		$2.1M Buy
26,389
+17,905
+211% +$1.06M ﹤0.01% 1850
2019
Q3 		$412K Sell
8,484
-20,516
-71% -$1.07M ﹤0.01% 2434
2019
Q2 		$1.52M Buy
29,000
+19,183
+195% +$1.1M ﹤0.01% 1988
2019
Q1 		$520K Sell
9,817
-28,312
-74% -$1.39M ﹤0.01% 2315
2018
Q4 		$1.55M Sell
38,129
-4,413
-10% -$165K ﹤0.01% 1855
2018
Q3 		$1.62M Sell
42,542
-4,641
-10% -$206K ﹤0.01% 2034
2018
Q2 		$2.13M Buy
47,183
+8,578
+22% +$391K ﹤0.01% 1916
2018
Q1 		$1.86M Sell
38,605
-9,730
-20% -$543K ﹤0.01% 1942
2017
Q4 		$1.9M Buy
+48,335
New +$1.81M ﹤0.01% 2033

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Allianz Asset Management's GBT Position: Q4 2022 in Review

Allianz Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 401,197 shares — an estimated $27.3M sold.

Allianz Asset Management first reported a position in GBT in Q4 2017 and held it in 13 quarters. The position peaked at $27.3M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Allianz Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Allianz Asset Management sold 401,197 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $27.3M.
  • Allianz Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 13 quarters.
  • Allianz Asset Management's Global Blood Therapeutics, Inc. position peaked at $27.3M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Allianz Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.